Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
586 7 |
Ultima descărcare din IBN: 2022-12-08 12:00 |
Căutarea după subiecte similare conform CZU |
615.2.074+543.544.5.068.7+546.32 (1) |
Medicaments according to their principal action (395) |
Physicochemical methods of analysis (other than optical methods) (59) |
Metals in general (36) |
SM ISO690:2012 MAZUR, Ecaterina, SCHMID, Martin, UNCU, Livia. Compatibility determination of potassium orotate with spironolactone by high-performance liquid chromatography. In: Moldovan Medical Journal, 2020, nr. 4(63), pp. 35-42. ISSN 2537-6373. DOI: https://doi.org/10.5281/zenodo.4016810 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Moldovan Medical Journal | ||||||
Numărul 4(63) / 2020 / ISSN 2537-6373 /ISSNe 2537-6381 | ||||||
|
||||||
DOI:https://doi.org/10.5281/zenodo.4016810 | ||||||
CZU: 615.2.074+543.544.5.068.7+546.32 | ||||||
Pag. 35-42 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background: Compatibility determination between active pharmaceutical ingredients (APIs) in fixed-dose combinations is an indispensable step in the elaboration. High-performance liquid chromatography provides information on possible interactions between APIs and their related interaction products. The purpose of the present study was to investigate the compatibility of potassium orotate in combination with spironolactone by a HPLC method. Material and methods: The detection was carried out using Liquid Chromatograph Agilent 1100 with UV-VIS detector and a RP-18 reversed column (250*4 mm, 5 μm), mobile phase of acetonitrile: phosphate buffer solution (pH=4.0) with the ratio 1:49 and 1:1, at flow rate 1 and 1.5 mL/min, injection volume 20 μL; potassium orotate and spironolactone substances were provided by Sigma Aldrich, USA. Results: Due to the developed method both separation and simultaneous qualitative and quantitative determination of APIs in the mechanical mixture were carried out. Spironolactone: retention time 6.9 min, concentration 98.1% (±0.21); potassium orotate: retention time 3.06 min, concentration 91.67% (±0.15). There were just well-separated symmetrical peaks of APIs and no additional peak in the chromatograms. Conclusions: There is compatibility between APIs. Further studies will be performed by other methods (DSC, FT-IF Spectrometry) to confirm the obtained result. |
||||||
Cuvinte-cheie HPLC, Combination, potassium orotate, spironolactone |
||||||
|